ASO Author Reflections: Evaluation of Neoadjuvant Chemotherapy in the Treatment of High-Grade Upper Tract Urothelial Carcinoma
ASO Author Reflections
- 11 Downloads
Long Wang has no conflicts of interest to disclose.
- 2.Birtle AJ, Lewis R, Johnson M, Hall E, POUT Trial Management Group (TMG). Time to define an international standard of postoperative care for resected upper urinary tract transitional cell carcinoma (TCC): opening of the peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (POUT) Trial. BJU Int. 2012;110:919–921.CrossRefGoogle Scholar
- 3.Hoffman-Censits J, Puligandla M, Trabulsi E, et al. LBA26 phase II trial of neoadjuvant chemotherapy followed by extirpative surgery for patients with high grade upper tract urothelial carcinoma (HG UTUC): results from ECOG-ACRIN 8141. J Urol. 2018;199(4 Suppl):e1166–e1167.Google Scholar
- 8.Lingxiao C, Zhenyu O, Ruizhe W, et al. Neoadjuvant chemotherapy benefits survival in high-grade upper tract urothelial carcinoma: a propensity score-based analysis. Ann Surg Oncol. Epub 18 Dec 2019. https://doi.org/10.1245/s10434-019-08128-7.
© Society of Surgical Oncology 2020